Skip to content
← Back to this collection

PUBLICATIONS · 19620491

Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2009 Aug 20
First author
Tsukimoto I

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Tsukimoto I
      type
      Author
    2. name
      Tawa A
      type
      Author
    3. name
      Horibe K
      type
      Author
    4. name
      Tabuchi K
      type
      Author
    5. name
      Kigasawa H
      type
      Author
    6. name
      Tsuchida M
      type
      Author
    7. name
      Yabe H
      type
      Author
    8. name
      Nakayama H
      type
      Author
    9. name
      Kudo K
      type
      Author
    10. name
      Kobayashi R
      type
      Author
    11. name
      Hamamoto K
      type
      Author
    12. name
      Imaizumi M
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Tsukimoto I
      type
      Author
    2. name
      Tawa A
      type
      Author
    3. name
      Horibe K
      type
      Author
    4. name
      Tabuchi K
      type
      Author
    5. name
      Kigasawa H
      type
      Author
    6. name
      Tsuchida M
      type
      Author
    7. name
      Yabe H
      type
      Author
    8. name
      Nakayama H
      type
      Author
    9. name
      Kudo K
      type
      Author
    10. name
      Kobayashi R
      type
      Author
    11. name
      Hamamoto K
      type
      Author
    12. name
      Imaizumi M
      type
      Author
    bibliography ids
    1. nci-bib-6ab9edf7318db099982f18d5
    book metadata
    content sha256
    55900aec41fa4cd244f1abc85b7a0d113509cf1258160e9bec621d977c777d64
    document type
    citation
    dois
    1. 10.1200/JCO.2008.18.7948
    electronic publication date
    display
    2009 Jul 20
    precision
    day
    year
    2009
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:19620491
    immutable id
    pubmed:19620491@55900aec41fa4cd244f1abc85b7a0d113509cf1258160e9bec621d977c777d64
    journal
    abbreviation
    J Clin Oncol
    issn electronic
    1527-7755
    issn print
    0732-183X
    issue
    24
    name
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    nlm unique id
    8309333
    pages
    4007-13
    volume
    27
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      19620491
      provenance
      batch id
      0706b5111d1451f52f74
      provider
      NCBI PubMed ESummary
      record sha256
      07140176b68b4633ef300d4041ecae37536b62c281687b93fd290f3a61efec78
      response sha256
      98b7635e326dbc32198e6976da57b1b6c18df77505740dee0ce67d80260cda70
      retrieved at
      2026-09-09T23:46:29.215195+00:00
      publication date
      display
      2009 Aug 20
      precision
      day
      year
      2009
      publication types
      1. Journal Article
      2. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/19620491/
      title
      Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.

      Preserved source evidence · Not medical advice